Ocular Paraneoplastic Syndromes.
Joanna Przeździecka-DołykAnna BrzeckaMaria EjmaMarta Misiuk-HojłoLuis Fernando Torres SolisArturo Solís HerreraSiva G SomasundaramCecil E KirklandGjumrakch AlievPublished in: Biomedicines (2020)
Ocular-involving paraneoplastic syndromes present a wide variety of clinical symptoms. Understanding the background pathophysiological and immunopathological factors can help make a more refined differential diagnosis consistent with the signs and symptoms presented by patients. There are two main pathophysiology arms: (1) autoimmune pathomechanism, which is presented with cancer-associated retinopathy (CAR), melanoma-associated retinopathy (MAR), cancer-associated cone dysfunction (CACD), paraneoplastic vitelliform maculopathy (PVM), and paraneoplastic optic neuritis (PON), and (2) ectopic peptides, which is often caused by tumor-expressed growth factors (T-exGF) and presented with bilateral diffuse uveal melanocytic proliferation (BDUMP). Meticulous systematic analysis of patient symptoms is a critical diagnostic step, complemented by multimodal imaging, which includes fundus photography, optical coherent tomography, fundus autofluorescence, fundus fluorescein angiography, electrophysiological examination, and sometimes fundus indocyjanin green angiography if prescribed by the clinician. Assessment of the presence of circulating antibodies is required for diagnosis. Antiretinal autoantibodies are highly associated with visual paraneoplastic syndromes and may guide diagnosis by classifying clinical manifestations in addition to monitoring treatment.
Keyphrases
- diabetic retinopathy
- optical coherence tomography
- end stage renal disease
- high resolution
- computed tomography
- optic nerve
- case report
- sleep quality
- newly diagnosed
- ejection fraction
- chronic kidney disease
- systemic lupus erythematosus
- peritoneal dialysis
- signaling pathway
- pain management
- patient reported outcomes
- physical activity
- low grade
- high grade
- skin cancer